Ameriprise Financial Inc Opened Huge Biodelivery Sciences International Inc Position

February 15, 2018 - By reb123z

 Ameriprise Financial Inc Opened Huge Biodelivery Sciences International Inc Position

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.67, from 1 in 2017Q2. It increased, as 8 investors sold BioDelivery Sciences International, Inc. shares while 7 reduced holdings. 6 funds opened positions while 19 raised stakes. 20.34 million shares or 6.83% more from 19.04 million shares in 2017Q2 were reported.

Broadfin Cap Ltd Liability Corp has invested 1.92% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Royal Retail Bank Of Canada reported 1,402 shares. Next Fincl Group reported 58,850 shares. Gsa Capital Prtn Llp reported 408,667 shares. Cutter & Brokerage reported 38,660 shares or 0.05% of all its holdings. Art Advisors Ltd Co stated it has 71,455 shares. Archford Strategies Limited Liability Company holds 0.04% or 40,000 shares. Blackrock accumulated 0% or 1.16M shares. Baker Bros Advsrs L P accumulated 210,021 shares. Renaissance Tech holds 585,200 shares or 0% of its portfolio. Deutsche Retail Bank Ag invested in 0% or 575,579 shares. California Employees Retirement invested in 259,400 shares. Alphamark Advisors Lc reported 1,100 shares. North Carolina-based Salem Investment Counselors Incorporated has invested 0.01% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Grp Inc One Trading L P reported 2,925 shares.

Since September 14, 2017, it had 0 buys, and 2 selling transactions for $2.51 million activity.

The New Ameriprise Financial Inc Holding in Biodelivery Sciences International Inc

Ameriprise Financial Inc reported SC 13G/A form with the SEC for Biodelivery Sciences International Inc. Access it here: 000119312518045346. As reported by Ameriprise Financial Inc, the filler owns 2.34% or 1,307,801 shares of the Health Care–company.

Biodelivery Sciences International Inc stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Ameriprise Financial Inc’s positive view for Biodelivery Sciences International Inc.

Biodelivery Sciences International Inc Institutional Sentiment

Filings show 125 investors own Biodelivery Sciences International Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 8980338. 50452610 were owned by these investors. 16 funds opened new Biodelivery Sciences International Inc stakes, 55 increased positions. There were 31 that closed positions and 35 reduced them.

Kevin Kotler Broadfin Capital Llc is an investor bullish on Biodelivery Sciences International Inc, owning 4744060 shares as of Q3 2015 for 1.47% of its portfolio. 1492 Capital Management Llc owns 497469 shares or 1.97% of its portfolio. NC Franklin Street Advisors Inc have 0.22% of its portfolio for 199375 shares. Further, Foresite Capital Management I Llc reported stake worth 29.31% of its portfolio. The NJ Condor Capital Management owns 12090 shares. Biodelivery Sciences International Inc is 0.02% of its portfolio.

Business Profile

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

SEC Form 13G.

Analysts await BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings on March, 16. They expect $-0.23 EPS, up 20.69 % or $0.06 from last year’s $-0.29 per share. After $-0.21 actual EPS reported by BioDelivery Sciences International, Inc. for the previous quarter, Wall Street now forecasts 9.52 % negative EPS growth.

The stock increased 1.15% or $0.025 during the last trading session, reaching $2.2. About 341,898 shares traded. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has risen 24.37% since February 15, 2017 and is uptrending. It has outperformed by 7.67% the S&P500.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $122.94 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 21.78 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Among 7 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioDelivery Sciences International has $14 highest and $300 lowest target. $5.93’s average target is 169.55% above currents $2.2 stock price. BioDelivery Sciences International had 32 analyst reports since August 16, 2015 according to SRatingsIntel. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) earned “Neutral” rating by Janney Capital on Tuesday, October 27. The firm earned “Overweight” rating on Monday, February 8 by Piper Jaffray. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Hold” rating given on Wednesday, May 11 by Cantor Fitzgerald. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Buy” rating given on Monday, July 24 by H.C. Wainwright. Piper Jaffray maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Wednesday, August 9 with “Buy” rating. FBR Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Wednesday, June 21 with “Buy” rating. The company was initiated on Wednesday, November 4 by Cantor Fitzgerald. H.C. Wainwright maintained the shares of BDSI in report on Friday, June 23 with “Buy” rating. The stock has “Overweight” rating by Cantor Fitzgerald on Wednesday, May 17. H.C. Wainwright maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Friday, June 9. H.C. Wainwright has “Buy” rating and $400 target.

More notable recent BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news were published by: Globenewswire.com which released: “BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical” on December 14, 2017, also Prnewswire.com with their article: “BioDelivery Sciences Participates in US Department of Health and Human …” published on October 06, 2017, Prnewswire.com published: “BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva” on October 12, 2017. More interesting news about BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were released by: Prnewswire.com and their article: “BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference” published on November 16, 2017 as well as Globenewswire.com‘s news article titled: “BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement …” with publication date: February 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.